AbbVie Inc.
https://www.abbvie.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AbbVie Inc.
AbbVie Claims Rinvoq Superiority To Dupixent In AD
In the first head-to-head study of Rinvoq versus Dupixent in atopic dermatitis, the AbbVie drug showed superiority on a composite endpoint measuring skin clearance and itch resolution.
Overall Survival Is Not A Required Primary Endpoint In All Cancer Trials, US FDA Says
Seeking to clear up a ‘misconception,’ Oncology Center of Excellence officials say earlier endpoints, such as progression-free survival and overall response, continue to be useful in getting therapies to market quicker, but sponsors still should plan to systematically collect OS data to ensure there is no detriment to survival.
Merck Investors Keeping A Close Watch On Winrevair Uptake
Some patients have already been prescribed the new drug for pulmonary arterial hypertension but Merck & Co. did not provide any sales or guidance.
‘It’s Not About Me’ – AstraZeneca’s Soriot Says His Pay Rise Will Help European Pharma
AstraZeneca’s CEO says his potential 11% pay rise is needed to help the European industry remain competitive with its higher paying US counterparts.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Luminera
- Mavupharma
- Pharmacyclics, Inc.
- Stemcentrx, Inc.
- Syndesi Therapeutics SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice